Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.47 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | THPO | P40225 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417758 | 0.86 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2SRPK1KDM4ECYP1A2 | |
| SCHEMBL15101008 | 0.86 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2SRPK1KDM4ECYP1A2 | |
| SCHEMBL19582507 | 0.85 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2SRPK1KDM4ECYP1A2 | |
| SCHEMBL25639667 | 0.85 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2ALDH1A1HRH3 | |
| SCHEMBL15093911 | 0.82 | LMNA (0.66) | LMNASMN1; SMN2KDM4ETSHRHSD17B10 | |
| SCHEMBL18914793 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2ADRB2KDM4EHSD17B10 | |
| SCHEMBL20503423 | 0.82 | ADRB2 (0.54) | LMNASMN1; SMN2ADRB2HTR1AHTR2C | |
| SCHEMBL29417642 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2ADRB2KDM4EHSD17B10 | |
| SCHEMBL20566963 | 0.82 | HRH3 (0.56) | LMNASMN1; SMN2ALDH1A1HTR6DRD2 | |
| SCHEMBL20503432 | 0.82 | LMNA (0.45) | LMNASMN1; SMN2CYP2D6TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-1697353-A2 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS WITH AFFINITY FOR 5-HT1 RECEPTORS | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050227980-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | PFIZER INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050227981-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005061491-A2 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS WITH AFFINITY FOR 5-HT1 RECEPTORS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227981-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | ARAF, MRPL21, ACSL3 | LMNA 2528/4885SMN1; SMN2 2882/4885KCNH2 2312/4885 |
| US-20050227980-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | ARAF, MRPL21, ACSL3 | LMNA 2528/4885SMN1; SMN2 2882/4885KCNH2 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.